Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAXIO: Carboplatin + Paclitaxel + Durvalumab in First Line Extensive Disease SCLC
NCT05856695Phase 2Active, not recruiting
- Sponsor
- IFCT
- Start
- Nov 2023
- Primary completion
- Nov 2026
- Modality
- Antibody Conjugates, Small Molecules, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, Paclitaxel Micelles for Injection in small cell lung cancer (SCLC), sponsored by IFCT. Started Nov 2023; status: active, not recruiting.
02
Drugs
durvalumabPaclitaxel Micelles for Injection
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05856695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05856695.